A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Senaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms FLAMES
- Sponsors IMPACT Therapeutics
Most Recent Events
- 16 Jan 2025 According to IMPACT Therapeutics media release , Senaparib have been approved for marketing by the National Medical Products Administration (NMPA) for the maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer after achieving complete remission or partial remission of first-line platinum-containing chemotherapy based on this study.
- 24 Oct 2023 Results (as of 16 Mar. 2023, n=403) assessing efficacy and safety of senaparib as maintenance treatment in in patients with newly diagnosed advanced ovarian cancer presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Primary endpoint has been met. (PFS)